Insider Selling: Phreesia (NYSE:PHR) Insider Sells $29,647.80 in Stock

Phreesia, Inc. (NYSE:PHR) insider Evan Roberts sold 1,810 shares of Phreesia stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $16.38, for a total transaction of $29,647.80. Following the completion of the sale, the insider directly owned 832,822 shares in the company, valued at approximately $13,641,624.36. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Evan Roberts also recently made the following trade(s):

• On Friday, January 16th, Evan Roberts sold 6,268 shares of Phreesia stock. The shares were sold at an average price of $16.36, for a total transaction of $102,544.48.
• On Thursday, January 8th, Evan Roberts sold 6,317 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total transaction of $107,452.17.

Phreesia Trading Up 1.2%

NYSE:PHR opened at $15.80 on Friday. Phreesia, Inc. has a 12 month low of $15.40 and a 12 month high of $32.76. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $17.81 and its 200 day moving average is $22.98. The stock has a market capitalization of $952.58 million, a PE ratio of -157.98 and a beta of 0.61.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same period last year, the business posted ($0.25) earnings per share. Sell-side analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several hedge funds have recently bought and sold shares of PHR. Massachusetts Financial Services Co. MA bought a new stake in Phreesia during the 4th quarter worth approximately $231,000. Moody National Bank Trust Division grew its position in shares of Phreesia by 63.8% during the 4th quarter. Moody National Bank Trust Division now owns 195,944 shares of the company’s stock valued at $3,315,000 after purchasing an additional 76,345 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Phreesia in the fourth quarter worth $1,203,000. Diversified Trust Co. increased its holdings in shares of Phreesia by 12.2% in the fourth quarter. Diversified Trust Co. now owns 51,422 shares of the company’s stock worth $870,000 after purchasing an additional 5,600 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Phreesia in the third quarter worth $4,173,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on PHR shares. Citigroup dropped their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, January 9th. KeyCorp dropped their price target on shares of Phreesia from $35.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. BMO Capital Markets began coverage on shares of Phreesia in a report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 price objective for the company. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Truist Financial set a $24.00 target price on shares of Phreesia in a report on Thursday, January 8th. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.06.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.